Neuroactive Steroids. 2.3α-Hydroxy-3β-methyl-21-(4-cyano-1H-pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor

被引:93
作者
Botella, Gabriel Martinez [1 ,4 ]
Salituro, Francesco G. [1 ]
Harrison, Boyd L. [1 ]
Beresis, Richard T. [2 ]
Bai, Zhu [3 ]
Blanco, Maria-Jesus [1 ]
Belfort, Gabriel M. [1 ,5 ]
Dai, Jing [1 ]
Loya, Carlos M. [1 ,6 ]
Ackley, Michael A. [1 ]
Althaus, Alison L. [1 ]
Grossman, Scott J. [1 ]
Hoffmann, Ethan [1 ]
Doherty, James J. [1 ]
Robichaud, Albert J. [1 ]
机构
[1] Sage Therapeut Inc, 215 First St, Cambridge, MA 02142 USA
[2] Shanghai Chempartner, 998 Halei Rd, Shanghai 201203, Peoples R China
[3] WuXi AppTec, 288 Fute Zhong Rd, Shanghai 200131, Peoples R China
[4] Praxis Precis Med, Cambridge, MA USA
[5] Takeda Pharmaceut Inc, Osaka, Japan
[6] Collegium Pharmaceut Inc, Canton, MA USA
关键词
GABA(A) RECEPTORS; ANTIEPILEPTIC DRUGS; EILAT CONFERENCE; PROGRESS REPORT; NEUROSTEROIDS; BINDING; SUBUNIT;
D O I
10.1021/acs.jmedchem.7b00846
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Certain classes of neuroactive steroids (NASs) are positive allosteric modulators (PAM) of synaptic and extrasynaptic GABA(A) receptors. Herein, we report new SAR insights in a series of 5 beta-nor-19-pregnan-20-one analogues bearing substituted pyrazoles and triazoles at C-21, culminating in the discovery of 3 alpha-hydroxy-3 beta-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5 beta-pregnan-20-one (SAGE -217, 3), a potent GABA(A) receptor modulator at both synaptic and extrasynaptic receptor subtypes, with excellent oral DMPK properties. Compound 3 has completed a phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial and is currently being studied in parallel phase 2 clinical trials for the treatment of postpartum depression (PPD), major depressive disorder (MDD), and essential tremor (ET).
引用
收藏
页码:7810 / 7819
页数:10
相关论文
共 30 条
  • [1] Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors
    Abramian, Armen M.
    Comenencia-Ortiz, Eydith
    Modgil, Amit
    Vien, Thuy N.
    Nakamura, Yasuko
    Moore, Yvonne E.
    Maguire, Jamie L.
    Terunuma, Miho
    Davies, Paul A.
    Moss, Stephen J.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2014, 111 (19) : 7132 - 7137
  • [2] Althaus A. L., UNPUB
  • [3] Two tyrosine residues on the alpha subunit are crucial for benzodiazepine binding and allosteric modulation of gamma-aminobutyric acid(A) receptors
    Amin, J
    BrooksKayal, A
    Weiss, DS
    [J]. MOLECULAR PHARMACOLOGY, 1997, 51 (05) : 833 - 841
  • [4] [Anonymous], 2015, STUD SAGE 547 SUP RE
  • [5] Extrasynaptic GABAA Receptors: Form, Pharmacology, and Function
    Belelli, Delia
    Harrison, Neil L.
    Maguire, Jamie
    Macdonald, Robert L.
    Walker, Matthew C.
    Cope, David W.
    [J]. JOURNAL OF NEUROSCIENCE, 2009, 29 (41) : 12757 - 12763
  • [6] Bialer M, 2017, EPILEPSIA, V58, P181, DOI [10.1111/epi.14557, 10.1111/epi.13634]
  • [7] Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
    Bialer, Meir
    Johannessen, Svein I.
    Levy, Rene H.
    Perucca, Emilio
    Tomson, Torbjorn
    White, H. Steve
    [J]. EPILEPSY RESEARCH, 2015, 111 : 85 - 141
  • [8] Neuroactive Steroids. 1. Positive Allosteric Modulators of the (γ-Aminobutyric Acid)A Receptor: Structure-Activity Relationships of Heterocyclic Substitution at C-21
    Botella, Gabriel Martinez
    Salituro, Francesco G.
    Harrison, Boyd L.
    Beresis, Richard T.
    Bai, Zhu
    Shen, Kaisheng
    Belfort, Gabriel M.
    Loya, Carlos M.
    Ackley, Michael A.
    Grossman, Scott J.
    Hoffmann, Ethan
    Jia, Shiling
    Wang, Jiamiao
    Doherty, James J.
    Robichaud, Albert J.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (08) : 3500 - 3511
  • [9] GABAergic dysfunction in mood disorders
    Brambilla, P
    Perez, J
    Barale, F
    Schettini, G
    Soares, JC
    [J]. MOLECULAR PSYCHIATRY, 2003, 8 (08) : 721 - 737
  • [10] Ellenbogen A, 2016, NEUROLOGY, V86